Skip to navigation Skip to content

Clinical Trial: A Teleheath tDCS Approach to Decrease Cannabis Use

Share

Details
Type of MS: RRMS
Treatment mode of action: To reduce cannabis use
Number of Subjects: 46
Medication: tDCS and mindfulness meditation
Location: Alabama|Alaska|Arizona|Arkansas|California|Colorado|Connecticut|Delaware|District of Columbia|Florida|Georgia|Hawaii|Idaho|Illinois|Indiana|Iowa|Kansas|Kentucky|Louisiana|Maine|Maryland|Massachusetts|Michigan|Minnesota|Mississippi|Missouri|Montana|Nebraska|Nevada|New Hampshire|New Jersey|New Mexico|New York|North Carolina|North Dakota|Ohio|Oklahoma|Oregon|Pennsylvania|Rhode Island|South Carolina|South Dakota|Tennessee|Texas|Utah|Vermont|Virginia|Washington|West Virginia|Wisconsin|Wyoming
Institutions: NYU Langone Contact Information
Eric McConathey
929-455-5088
eric.mcconathey@nyulangone.org

Funding:

National Institute of Health

Description

Researchers at NYU Langone Health, Multiple Sclerosis Comprehensive Care Center, are recruiting women with RRMS (ages 21 to 65) who regularly use any cannabis product (e.g., marijuana, edibles, vaping) and who wish to reduce cannabis use. The research study will be a one-month treatment using transcranial direct current stimulation (tDCS) and mindfulness meditation. tDCS is safe and well-tolerated, and requires a daily (20 min) session. This study is completed through televisits, and all study procedures are completed by you at home. The study will take place over a period of about 4.5 months and involves 22 virtual visits that will be completed remotely from your home using Zoom. Compensation is provided for your time. 
 

Share


© 2022 The National Multiple Sclerosis Society is a tax exempt 501(c)3 nonprofit organization. Its Identification Number (EIN) is 13-5661935.